Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019 Alterity Therapeutics

Chairman’s Address to Shareholders 2019 AGM

Post navigation

AGM 2019 Presentation

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Related Posts

Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial

June 30, 2015

Prana Completes Recruitment in Alzheimer’s Trial

July 17, 2013

Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease

September 8, 2014

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference
Alterity to present at the 7th International Congress of Multiple System Atrophy
Alterity Half Year Results and Investor Webcast Notification
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065